Cumberland Pharmaceuticals (CPIX) Long-Term Investments (2025 - 2026)
Cumberland Pharmaceuticals (CPIX) reported Long-Term Investments of $3.8 million for Q1 2026, down 3.66% sequentially from $4.0 million in Q4 2025.
Cumberland Pharmaceuticals (CPIX) Long-Term Investments (2025 - 2026) Analysis & Trends
Cumberland Pharmaceuticals (CPIX) has 2 years of Long-Term Investments data on file, last reported at $3.8 million in Q1 2026.
- For the quarter ending Q1 2026, Long-Term Investments changed N/A year-over-year to $3.8 million; the trailing twelve-month figure through Mar 2026 stood at $3.8 million (changed N/A YoY), and the FY2025 full-year result was $4.0 million, changed N/A from the prior year.
- Long-Term Investments fell to $3.8 million in Q1 2026, from $4.0 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $4.0 million in Q4 2025 to a low of $3.8 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 56.09 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.32 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 702.35 Mn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 146.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Cumberland Pharmaceuticals | 104.57 Mn | 93.23 Mn | 7.20 Mn | 3.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.84 Mn |
| Dec 31, 2025 | 3.99 Mn |